ASH 2022 Conference Coverage

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

ASH 2022 Conference Coverage

Lymphoma
Leukemia
Myeloma
MDS and MPN
Benign Hematology

Playback speed

10 seconds

ASH 2022 SubQ Isatuximab + Carfilzomib & Dexamethasone in Relapsed MM: Ikema Subgroup Analysis by Number of Prior Lines of Treatment

By ASH 2022 Conference Coverage FEATURING Hang Quach

170 views

January 4, 2023

Comments 0

Optimizing the Management of Patients with Polycythemia Vera (PV)

Feat. P. Bose, R. Rampal

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Myeloma

ASH 2022 Phase 1/2 Results From MonumenTAL-1: Talquetamab, a G Prote…

ASH 2022 Conference Coverage

A. Chari

206 views

ASH 2022 Results of the ASCENT Trial: Fixed Duration Therapy With Da…

ASH 2022 Conference Coverage

S. Kumar

79 views

ASH 2022 Mezigdomide (CC-92480) + Dex in R/R MM: Preliminary Results…

ASH 2022 Conference Coverage

P. Richardson

178 views

ASH 2022: First Relapse in Multiple Myeloma - How to Pick the Next B…

ASH 2022 Conference Coverage

Y. Efebera

225 views

IKEMA Subgroup Analysis: Isatuximab + Carfilzomib & Dexamethasone in…

ASH 2022 Conference Coverage

T. Martin

1.5K views

ASH 2022 Subsequent Antimyeloma Therapies From ICARIA-MM Study: Pom/…

ASH 2022 Conference Coverage

P. Richardson

109 views

ASH 2022 Phase 3 EMagine/CARTITUDE-6 Trial: DVRd Followed by either …

ASH 2022 Conference Coverage

P. Sonneveld

122 views

ASH 2022 MAIA Trial Age Subgroup Analysis: Daratumumab + Lenalidomid…

ASH 2022 Conference Coverage

T. Plesner

81 views

ASH 2022: A Consultant’s Guide to Smoldering Multiple Myeloma

ASH 2022 Conference Coverage

S. Thorsteinsdottir

135 views

ASH 2022 SubQ Isatuximab + Carfilzomib & Dexamethasone in Relapsed M…

ASH 2022 Conference Coverage

H. Quach

170 views

ASH 2022 Understanding and Monitoring Resistance to Anti-CD38 and -B…

ASH 2022 Conference Coverage

F. Pichiorri

203 views

ASH 2022 Gene Edited Off-the-Shelf NK Cells for Treating Hematologic…

ASH 2022 Conference Coverage

J. Miller

80 views

ASH 2022 Phase II DEDALO Trial: Daratumumab + Pomalidomide & Dexamet…

ASH 2022 Conference Coverage

V. Montefusco

43 views

Assessing Disease Risk in Multiple Myeloma: High or Low?

ASH 2022 Conference Coverage

T. Schmidt

142 views

ASH 2022 Phase 1 MagnetisMM-1 Trial: Elranatamab, a BCMA Targeted T-…

ASH 2022 Conference Coverage

N. S. Raje

64 views

U.S. Myeloma CAR-T Consortium Real World Experience: Factors Associa…

ASH 2022 Conference Coverage

H. Hashmi

217 views

ASH 2022 Once Weekly Selinexor, Carfilzomib & Dexamethasone (XKd) in…

ASH 2022 Conference Coverage

G. Schiller

52 views

ASH 2022 Maintenance Therapy Cessation for Sustained MRD Negative MM…

ASH 2022 Conference Coverage

N. Korde

413 views

ASH 2022 Phase 1/2 LINKER-MM1 Study of Linvoseltamab, a BCMAxCD3 Bis…

ASH 2022 Conference Coverage

N. Bumma

91 views

ASH 2022 Phase 3 VITAL Study: Survival Benefit of Birtamimab in Mayo…

ASH 2022 Conference Coverage

M. Gertz

78 views

ASH 2022 Outcomes of Penta-Refractory MM Patients Based on Access to…

ASH 2022 Conference Coverage

S. Atrash

136 views

Novel Approaches to Myeloma Burden Assessment

ASH 2022 Conference Coverage

T. Kourelis

261 views

ASH 2022 Neurotoxicity With Motor Symptoms After BCMA-Directed CAR-T…

ASH 2022 Conference Coverage

S. Parekh

74 views

ASH 2022 Myeloma XI Trial: Defining the Optimal Duration of Lenalido…

ASH 2022 Conference Coverage

G. Morgan

906 views

ASH 2022 Phase I Dose-Escalation Study of Forimtamig (RG6234), a GPR…

ASH 2022 Conference Coverage

C. Carlo-Stella

55 views

ASH 2022 GRIFFIN Trial Final Analysis: D-RVd in Clinically Relevant …

ASH 2022 Conference Coverage

A. Chari

768 views